Menu

Interferon Discoverer Dies

Jean Lindemann, the virologist who helped figure out that interferons were responsible for anti-viral responses, has passed away at age 90.

Jan 26, 2015
Kerry Grens

WIKIMEDIA, MRC NATIONAL INSTITUTE FOR MEDICAL RESEARCHJean Lindenmann, the virologist who, along with Alick Isaacs at the National Institute for Medical Research in London, helped identify interferons for the first time passed away earlier this month (January 15). He was 90.

Lindenmann was a postdoc in the 1950s when he and Isaacs discovered that interferons were responsible for blocking future infections after chicken egg membranes had been exposed to an inactivated form of the virus.

According to The New York Times (NYT), “[a]fter his discovery, Dr. Lindenmann returned to his original institution, the University of Zurich, saying he wanted to leave further study of interferons to others.” Lindenmann sought an answer to a phenomenon in laboratory mice that some were resistant to influenza and others not. “The answer turned out to be interferon again,” according to the NYT.

In 1987, upon the 30th anniversary of the discovery of interferon, the Journal of Interferon published a special issue devoted to Lindenmann. Then editor-in-chief Charles Weismann wrote: “Not many scientists have the satisfaction of laying the foundations for a new field of research, and not only living to see its successful evolution but also contributing significantly, time and again, to its development.”

Lindenmann is survived by two sons and four grandchildren.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.